Annual CFF
-$119.30 K
-$7.41 M-101.64%
31 December 2023
Summary:
Evoke Pharma annual cash flow from financing activities is currently -$119.30 thousand, with the most recent change of -$7.41 million (-101.64%) on 31 December 2023. During the last 3 years, it has fallen by -$9.15 million (-101.32%). EVOK annual CFF is now -100.44% below its all-time high of $27.12 million, reached on 31 December 2013.EVOK Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$2.98 M
+$2.68 M+907.74%
30 September 2024
Summary:
Evoke Pharma quarterly cash flow from financing activities is currently $2.98 million, with the most recent change of +$2.68 million (+907.74%) on 30 September 2024. Over the past year, it has increased by +$2.98 million (+100.00%). EVOK quarterly CFF is now -87.02% below its all-time high of $22.96 million, reached on 30 September 2013.EVOK Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$10.70 M
+$2.98 M+38.60%
30 September 2024
Summary:
Evoke Pharma TTM cash flow from financing activities is currently $10.70 million, with the most recent change of +$2.98 million (+38.60%) on 30 September 2024. Over the past year, it has increased by +$10.70 million (+100.00%). EVOK TTM CFF is now -60.55% below its all-time high of $27.12 million, reached on 31 December 2013.EVOK TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EVOK Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -101.6% | +100.0% | +100.0% |
| 3 y3 years | -101.3% | +851.7% | -36.8% |
| 5 y5 years | -102.6% | +2307.0% | +84.5% |
EVOK Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -100.9% | at low | -60.5% | +2597.8% | -36.8% | +9068.1% |
| 5 y | 5 years | -100.9% | at low | -77.2% | +2597.8% | -51.5% | +9068.1% |
| alltime | all time | -100.4% | +57.1% | -87.0% | +209.5% | -60.5% | +1646.3% |
Evoke Pharma Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $2.98 M(+907.7%) | $10.70 M(+38.6%) |
| June 2024 | - | $295.70 K(-96.1%) | $7.72 M(+4.0%) |
| Mar 2024 | - | $7.54 M(-6422.5%) | $7.42 M(-6322.5%) |
| Dec 2023 | -$119.30 K(-101.6%) | -$119.30 K(<-9900.0%) | -$119.30 K(<-9900.0%) |
| Sept 2023 | - | $0.00(0.0%) | $0.00(0.0%) |
| June 2023 | - | $0.00(0.0%) | $0.00(-100.0%) |
| Mar 2023 | - | $0.00(0.0%) | $7.12 M(-2.4%) |
| Dec 2022 | $7.29 M(-45.7%) | $0.00(0.0%) | $7.29 M(0.0%) |
| Sept 2022 | - | $0.00(-100.0%) | $7.29 M(-4.1%) |
| June 2022 | - | $7.12 M(+4053.6%) | $7.61 M(+1335.2%) |
| Mar 2022 | - | $171.50 K(>+9900.0%) | $530.10 K(-96.1%) |
| Dec 2021 | $13.43 M(+48.6%) | $0.00(-100.0%) | $13.43 M(-20.7%) |
| Sept 2021 | - | $313.10 K(+588.1%) | $16.93 M(+1.3%) |
| June 2021 | - | $45.50 K(-99.7%) | $16.72 M(-24.3%) |
| Mar 2021 | - | $13.07 M(+273.5%) | $22.08 M(+144.4%) |
| Dec 2020 | $9.04 M(+47.9%) | $3.50 M(+3372.0%) | $9.04 M(+54.7%) |
| Sept 2020 | - | $100.80 K(-98.1%) | $5.84 M(-0.4%) |
| June 2020 | - | $5.41 M(>+9900.0%) | $5.87 M(+6.8%) |
| Mar 2020 | - | $21.30 K(-93.1%) | $5.49 M(-10.1%) |
| Dec 2019 | $6.11 M(+32.2%) | $306.70 K(+147.7%) | $6.11 M(+5.3%) |
| Sept 2019 | - | $123.80 K(-97.5%) | $5.80 M(-15.5%) |
| June 2019 | - | $5.04 M(+692.0%) | $6.86 M(+45.7%) |
| Mar 2019 | - | $636.40 K(>+9900.0%) | $4.71 M(+2.0%) |
| Dec 2018 | $4.62 M | $0.00(-100.0%) | $4.62 M(0.0%) |
| Sept 2018 | - | $1.19 M(-58.9%) | $4.62 M(+32.4%) |
| June 2018 | - | $2.89 M(+430.1%) | $3.49 M(+482.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2018 | - | $544.60 K(>+9900.0%) | $599.00 K(-91.9%) |
| Dec 2017 | $7.39 M(-18.1%) | $0.00(-100.0%) | $7.39 M(+0.0%) |
| Sept 2017 | - | $56.90 K(-2376.0%) | $7.39 M(-53.8%) |
| June 2017 | - | -$2500.00(-100.0%) | $16.00 M(-1.6%) |
| Mar 2017 | - | $7.33 M(<-9900.0%) | $16.26 M(+80.2%) |
| Dec 2016 | $9.02 M(+79.4%) | -$3200.00(-100.0%) | $9.02 M(-4.3%) |
| Sept 2016 | - | $8.67 M(+3243.2%) | $9.43 M(+128.8%) |
| June 2016 | - | $259.30 K(+162.7%) | $4.12 M(-10.3%) |
| Mar 2016 | - | $98.70 K(-75.6%) | $4.60 M(-8.6%) |
| Dec 2015 | $5.03 M(+244.6%) | $404.80 K(-88.0%) | $5.03 M(-44.9%) |
| Sept 2015 | - | $3.36 M(+357.2%) | $9.13 M(+57.1%) |
| June 2015 | - | $734.90 K(+38.2%) | $5.81 M(+147.0%) |
| Mar 2015 | - | $531.60 K(-88.2%) | $2.35 M(+61.1%) |
| Dec 2014 | $1.46 M(-94.6%) | $4.50 M(>+9900.0%) | $1.46 M(-311.0%) |
| Sept 2014 | - | $42.90 K(-101.6%) | -$691.90 K(-103.1%) |
| June 2014 | - | -$2.72 M(+654.9%) | $22.23 M(-10.2%) |
| Mar 2014 | - | -$360.60 K(-115.4%) | $24.76 M(-8.7%) |
| Dec 2013 | $27.12 M(+2612.1%) | $2.35 M(-89.8%) | $27.12 M(+9.5%) |
| Sept 2013 | - | $22.96 M(<-9900.0%) | $24.77 M(+781.4%) |
| June 2013 | - | -$189.30 K(-109.5%) | $2.81 M(-6.3%) |
| Mar 2013 | - | $2.00 M(>+9900.0%) | $3.00 M(+200.0%) |
| Dec 2012 | $1.00 M(-460.0%) | $0.00(-100.0%) | $1.00 M(0.0%) |
| Sept 2012 | - | $1.00 M(>+9900.0%) | $1.00 M(>+9900.0%) |
| June 2012 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2012 | - | $0.00 | $0.00 |
| Dec 2011 | -$277.80 K | - | - |
FAQ
- What is Evoke Pharma annual cash flow from financing activities?
- What is the all time high annual CFF for Evoke Pharma?
- What is Evoke Pharma annual CFF year-on-year change?
- What is Evoke Pharma quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Evoke Pharma?
- What is Evoke Pharma quarterly CFF year-on-year change?
- What is Evoke Pharma TTM cash flow from financing activities?
- What is the all time high TTM CFF for Evoke Pharma?
- What is Evoke Pharma TTM CFF year-on-year change?
What is Evoke Pharma annual cash flow from financing activities?
The current annual CFF of EVOK is -$119.30 K
What is the all time high annual CFF for Evoke Pharma?
Evoke Pharma all-time high annual cash flow from financing activities is $27.12 M
What is Evoke Pharma annual CFF year-on-year change?
Over the past year, EVOK annual cash flow from financing activities has changed by -$7.41 M (-101.64%)
What is Evoke Pharma quarterly cash flow from financing activities?
The current quarterly CFF of EVOK is $2.98 M
What is the all time high quarterly CFF for Evoke Pharma?
Evoke Pharma all-time high quarterly cash flow from financing activities is $22.96 M
What is Evoke Pharma quarterly CFF year-on-year change?
Over the past year, EVOK quarterly cash flow from financing activities has changed by +$2.98 M (+100.00%)
What is Evoke Pharma TTM cash flow from financing activities?
The current TTM CFF of EVOK is $10.70 M
What is the all time high TTM CFF for Evoke Pharma?
Evoke Pharma all-time high TTM cash flow from financing activities is $27.12 M
What is Evoke Pharma TTM CFF year-on-year change?
Over the past year, EVOK TTM cash flow from financing activities has changed by +$10.70 M (+100.00%)